Biointron is excited to announce our participation in Swiss Biotech Day 2025, taking place on May 5-6, 2025, in Basel, Switzerland.

These past few weeks, several antibody drug startups have progressed from the pre-seed stage to final funding rounds. In the pre-seed stage, the focus is on early research, often funded by founders, grants, or angel investors. As the company progresses to the seed stage, it seeks additional funding to validate its scientific concept and develop initial prototypes, attracting early-stage venture capital.

Antibody-drug conjugates (ADCs) have revolutionized the landscape of oncology by delivering targeted therapies that minimize damage to healthy cells while maximizing the impact on cancerous tissues. However, researchers and clinicians are now exploring the many therapeutic possibilities of ADCs in treating a variety of non-cancerous conditions such as autoimmune, infectious, neurological, cardiovascular, and metabolic diseases.

Antibody drugs in ophthalmology represent a significant advancement in treating various eye diseases. These biologics target specific proteins involved in pathological processes, such as vascular endothelial growth factor (VEGF), which plays a key role in conditions like age-related macular degenera

BIO International Convention 2024は、2024年6月3日～6日にカリフォルニア州サンディエゴで開催されました。18,500人以上の業界リーダーが参加する、バイオテクノロジー分野で最大規模のイベントであり、最新の技術進展が共有されました。注目トピックには、AIとデジタルヘルス、次世代バイオ医薬品などが含まれます。

治療薬の構想から開発、そして市場投入に至るまでの道のりは、複雑かつ多面的なプロセスです。この過程には、探索、特性評価、製造、臨床試験など、多くのステップが含まれ、それぞれに独自の課題や要件があります。その複雑さを考慮して、多くの製薬・バイオテクノロジー企業は、このプロセスを効率化・加速するために専門的なパートナーに依頼しています。